NVS Jan 2026 97.500 put
| Previous close | 9.30 |
| Open | 9.30 |
| Bid | 5.20 |
| Ask | 5.80 |
| Strike | 97.50 |
| Expiry date | 2026-01-16 |
| Day's range | 9.30 - 9.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 11 |
GlobeNewswireNovartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
Primary results of the Scemblix® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ASCO Press Program and the EHA Plenary SessionLatest data from the Kisqali®* NATALEE trial, including efficacy endpoints for patients with node-negative stage II and III HR+/HER2- early breast cancerNew radioligand therapy portfolio data supporting overall platform leadership and ongoing expansion in research infrastructure an
- Thomson Reuters StreetEvents
Q1 2024 Legend Biotech Corp Earnings Call
Q1 2024 Legend Biotech Corp Earnings Call
GlobeNewswireArvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for
